Literature DB >> 17149651

Progressive myopia due to posterior staphyloma in Type I Osteogenesis Imperfecta.

Andrew Scott1, Shahram Kashani, Hamish M A Towler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17149651     DOI： 10.1007/s10792-006-9012-y

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN： 0165-5701            Impact factor:   2.031


× No keyword cloud information.
  5 in total

1.  Central corneal thickness is lower in osteogenesis imperfecta and negatively correlates with the presence of blue sclera.

Authors:  Cem Evereklioglu; Ercan Madenci; Yildirim A Bayazit; Kutluhan Yilmaz; Ayşe Balat; Necdet A Bekir
Journal:  Ophthalmic Physiol Opt       Date:  2002-11       Impact factor: 3.117

2.  Natural history of blue sclerae in osteogenesis imperfecta.

Authors:  D Sillence; B Butler; M Latham; K Barlow
Journal:  Am J Med Genet       Date:  1993-01-15

3.  Ocular findings in osteogenesis imperfecta congenita.

Authors:  C C Chan; W R Green; Z C de la Cruz; A Hillis
Journal:  Arch Ophthalmol       Date:  1982-09

Review 4.  Role of the sclera in the development and pathological complications of myopia.

Authors:  Neville A McBrien; Alex Gentle
Journal:  Prog Retin Eye Res       Date:  2003-05       Impact factor: 21.198

5.  Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2.

Authors:  B Sykes; D Ogilvie; P Wordsworth; G Wallis; C Mathew; P Beighton; A Nicholls; F M Pope; E Thompson; P Tsipouras
Journal:  Am J Hum Genet       Date:  1990-02       Impact factor: 11.025
  5 in total
  4 in total

1.  Osteogenesis imperfecta and the teeth, eyes, and ears-a study of non-skeletal phenotypes in adults.

Authors:  J D Hald; L Folkestad; C Z Swan; J Wanscher; M Schmidt; H Gjørup; D Haubek; C-H Leonhard; D A Larsen; J Ø Hjortdal; T Harsløf; M Duno; A M Lund; J-E B Jensen; K Brixen; B Langdahl
Journal:  Osteoporos Int       Date:  2018-08-24       Impact factor: 4.507

2.  Ocular characteristics and complications in patients with osteogenesis imperfecta: a systematic review.

Authors:  Sanne Treurniet; Pia Burger; Ebba A E Ghyczy; Frank D Verbraak; Katie R Curro-Tafili; Dimitra Micha; Nathalie Bravenboer; Stuart H Ralston; Ralph de Vries; Annette C Moll; Elisabeth Marelise W Eekhoff
Journal:  Acta Ophthalmol       Date:  2021-05-19       Impact factor: 3.988

3.  Assessing disease experience across the life span for individuals with osteogenesis imperfecta: challenges and opportunities for patient-reported outcomes (PROs) measurement: a pilot study.

Authors:  Laura L Tosi; Marianne K Floor; Christina M Dollar; Austin P Gillies; Tracy S Hart; David D Cuthbertson; V Reid Sutton; Jeffrey P Krischer
Journal:  Orphanet J Rare Dis       Date:  2019-01-29       Impact factor: 4.123

4.  Intravitreal bevacizumab for treatment of choroidal neovascularization associated with osteogenesis imperfecta.

Authors:  Pukhraj Rishi; Ekta Rishi; Anusha Venkatraman
Journal:  Indian J Ophthalmol       Date:  2012 May-Jun       Impact factor: 1.848
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.